FORM 10-Q


                       Securities and Exchange Commission
                             Washington, D. C. 20549

      (Mark One)
            X    Quarterly Report Pursuant to Section 13 or 15(d)
            -        of the Securities Exchange Act of 1934


                       For Quarter Ended: August 31, 2001

                                        OR
             _   Transition Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                         Commission File Number: 0-14820

                                  IMMUCOR, INC.
             (Exact name of registrant as specified in its charter)


                  Georgia                                22-2408354
          (State or other jurisdiction of             (I.R.S. Employer
           incorporation or organization)            Identification No.)

          3130 Gateway Drive   P.O. Box 5625   Norcross, Georgia 30091-5625
          (Address of principal executive offices)               (Zip Code)


                  Registrant's telephone number: (770) 441-2051

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                    Yes X No

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

        As of October 12, 2001: Common Stock, $0.10 Par Value - 7,277,617


<PAGE>


<TABLE>
<CAPTION>


                                  IMMUCOR, INC.
                           CONSOLIDATED BALANCE SHEETS
---------------------------------------------------------------------------------------------------------------------------------


                                                                                         August 31, 2001        May 31, 2001
                                                                                       ------------------------------------------
ASSETS                                                                                     (Unaudited)            (Audited)

CURRENT ASSETS:
<S>                                                                                            <C>                   <C>
   Cash and cash equivalents                                                                   $ 4,140,886           $ 3,124,517
   Accounts receivable, trade - Net                                                             21,988,271            21,167,490
   Loan to officer                                                                                 395,826               395,826
   Inventories                                                                                  15,690,655            15,668,637
   Income taxes receivable                                                                         517,673               402,243
   Deferred income taxes                                                                           578,015               631,797
   Prepaid expenses and other                                                                    1,970,465               891,356
                                                                                       --------------------  --------------------

     Total current assets                                                                       45,281,791            42,281,866

LONG-TERM INVESTMENT - At cost                                                                   1,000,000             1,000,000

PROPERTY, PLANT AND EQUIPMENT - Net                                                             17,583,795            18,333,952

DEFERRED INCOME TAXES                                                                            1,525,936             1,525,936

OTHER ASSETS - Net                                                                               2,241,076             2,104,845

DEFERRED LICENSING COSTS - Net                                                                   1,576,697             1,652,102

EXCESS OF COST OVER NET TANGIBLE ASSETS ACQUIRED - Net                                          28,757,111            28,913,981
                                                                                       --------------------  --------------------

                                                                                               $97,966,406           $95,812,682
                                                                                       ====================  ====================
</TABLE>

















See notes to consolidated financial statements.


<PAGE>

<TABLE>
<CAPTION>

                                  IMMUCOR, INC.
                     CONSOLIDATED BALANCE SHEETS (continued)
----------------------------------------------------------------------------------------------------------------------------------


                                                                                          August 31,2001        May 31, 2001
                                                                                       -------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY                                                       (Unaudited)             (Audited)

CURRENT LIABILITIES:
   <S>                                                                                         <C>                   <C>
   Current portion of borrowings under bank line of credit agreements                       $   2,170,013         $    2,417,121
   Current portion of long-term debt                                                            5,329,548              5,563,363
   Note payable to related party                                                                  216,245                349,654
   Current portion of capital lease obligations                                                   765,867                768,142
   Accounts payable                                                                             9,762,827              8,647,066
   Income taxes payable                                                                            58,892                 23,102
   Accrued salaries and wages                                                                   1,207,346              1,530,772
   Deferred income taxes                                                                          154,029                 98,308
   Other accrued liabilities                                                                    4,233,901              3,561,676
                                                                                       ---------------------  --------------------

     Total current liabilities                                                                 23,898,668             22,959,204

BORROWINGS UNDER BANK LINE OF CREDIT AGREEMENTS                                                 3,124,439              3,268,740
LONG-TERM DEBT                                                                                 34,349,298             34,839,576
CAPITAL LEASE OBLIGATIONS                                                                       1,411,592              1,629,705

DEFERRED INCOME TAXES                                                                           3,064,766              3,119,402

OTHER LIABILITIES                                                                                 172,718                152,588

SHAREHOLDERS' EQUITY:
   Common stock - authorized 45,000,000 shares, $0.10 par value; issued and
     outstanding 7,277,617                                                                        727,762                727,762
   Additional paid-in capital                                                                  15,439,889             15,439,889
   Retained earnings                                                                           21,514,305             20,261,628
   Accumulated other comprehensive loss                                                        (5,737,031)            (6,585,812)
                                                                                       ---------------------  --------------------

     Total shareholders' equity                                                                31,944,925             29,843,467
                                                                                       ---------------------  --------------------

                                                                                            $  97,966,406          $  95,812,682
                                                                                       =====================  ====================

</TABLE>










See notes to consolidated financial statements.



<PAGE>

<TABLE>
<CAPTION>

                                  IMMUCOR, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)
                                                                Three Months Ended
                                                          August 31,       August 31,
                                                             2001             2000
                                                             ----             ----

<S>                                                     <C>              <C>
NET SALES.............................................  $   18,639,962   $   17,081,242

COST OF SALES.........................................       9,377,509        8,567,954
                                                        --------------   --------------
GROSS MARGIN..........................................       9,262,453        8,513,288

OPERATING EXPENSES:
     Research and development.........................         487,012          473,025
     Selling and marketing............................       2,479,609        3,181,462
     Distribution.....................................       1,433,708        1,427,601
     General and administrative.......................       2,498,919        2,369,910
     Amortization expense.............................         407,811          484,092
                                                        --------------   --------------
        Total operating expenses......................       7,307,059        7,936,090
                                                        --------------   --------------
INCOME FROM OPERATIONS................................       1,955,394          577,198
                                                        --------------   --------------
OTHER INCOME (EXPENSE):
     Interest income..................................           1,068            3,787
     Interest expense.................................      (1,152,418)        (865,715)
     Other - net......................................         672,580           85,301
                                                        --------------   --------------
        Total other...................................        (478,770)        (776,627)
                                                        --------------   --------------
INCOME (LOSS) BEFORE INCOME TAXES.....................       1,476,624         (199,429)
INCOME TAX EXPENSE....................................         223,948           16,002
                                                        --------------   --------------
NET INCOME (LOSS).....................................  $    1,252,676   $     (215,431)
                                                        ==============   ==============
Earnings (loss) per share:
     Basic............................................        $ 0.17           $(0.03)
                                                        ==============   ==============
     Diluted..........................................        $ 0.17           $(0.03)
                                                        ==============   ==============

Weighted average shares outstanding:
     Basic............................................       7,277,617        7,311,801
                                                        ==============   ==============
     Diluted..........................................       7,296,232        7,311,801
                                                        ==============   ==============
</TABLE>





See notes to consolidated financial statements.


<PAGE>



<TABLE>
<CAPTION>

                                  IMMUCOR, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)
-----------------------------------------------------------------------------------------------------------------------------
                                                                                                 Three Months Ended
                                                                                            August 31,        August 31,
                                                                                               2001              2000
                                                                                         ------------------------------------
OPERATING ACTIVITIES:
<S>                                                                                          <C>                 <C>
   Net income (loss)                                                                         $1,252,676          $(215,431)
   Adjustments to reconcile net income (loss) to net cash provided by (used in)
     operating activities:
     Depreciation and amortization of property and equipment                                    953,753            792,486
     Amortization of other assets and excess of cost over net tangible assets acquired          407,811            484,092
     Loss on retirement of property and equipment                                                99,267                  -
     Changes in operating assets and liabilities:
       Accounts receivable, trade                                                              (406,286)          (417,968)
       Income tax receivable                                                                    (88,147)          (538,857)
       Inventories                                                                              (22,018)        (1,196,548)
       Other current assets                                                                  (1,060,210)        (1,063,711)
       Accounts payable                                                                       1,115,761          1,364,369
       Income taxes payable                                                                      63,374             32,466
       Other current liabilities                                                                266,210            155,726
                                                                                         -----------------  -----------------
         Total adjustments                                                                    1,329,515           (387,945)
                                                                                         -----------------  -----------------

Cash provided by (used in) operating activities                                               2,582,191           (603,376)

INVESTING ACTIVITIES:
   Purchases of / deposits on property and equipment                                           (590,015)          (406,203)
   Decrease (increase) in other assets                                                                -             (4,765)
                                                                                         -----------------  -----------------

Cash used in investing activities                                                              (590,015)          (410,968)

FINANCING ACTIVITIES:
   Borrowings under line of credit agreements net of repayments                                (566,487)          (214,194)
   Proceeds from issuance of long term debt and capital lease obligations                             -          2,055,144
   Repayment of long-term debt and capital lease obligations                                 (1,141,782)                 -
   Borrowings (payments) of notes payable                                                      (133,409)           263,087
   Purchase and retirement of stock (184,500 shares)                                                  -         (1,484,713)
                                                                                         -----------------  ----------------

Cash (used in) provided by financing activities                                              (1,841,678)           619,324

EFFECT OF EXCHANGE RATE CHANGES ON CASH                                                         865,871           (275,668)
                                                                                         -----------------  ---------------

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                                              1,016,369           (670,688)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                                              3,124,517          3,505,926
                                                                                         -----------------  ----------------

CASH AND CASH EQUIVALENTS AT END OF PERIOD                                                   $4,140,886         $2,835,238
                                                                                         =================  ================
</TABLE>


See notes to consolidated financial statements


<PAGE>


                                  IMMUCOR, INC.
                   Notes to Consolidated Financial Statements
                                   (Unaudited)

1.  BASIS OF PRESENTATION

The accompanying  unaudited consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States
for interim financial  information and the instructions to Form 10-Q and Article
10 of Regulation  S-X.  Accordingly,  they do not include all of the information
and footnotes required by accounting principles generally accepted in the United
States for complete financial  statements.  However,  there has been no material
change in the information disclosed in the Company's annual financial statements
dated May 31, 2001,  except as disclosed  herein.  In the opinion of management,
all adjustments  (consisting of normal recurring accruals)  considered necessary
for  a  fair  presentation  have  been  included.   Operating  results  for  the
three-month  period ended August 31, 2001 are not necessarily  indicative of the
results  that may be  expected  for the year  ending May 31,  2002.  For further
information,  refer  to the  consolidated  financial  statements  and  footnotes
thereto  included in the Company's Annual Report on Form 10-K for the year ended
May 31, 2001.


2.  INVENTORIES

Inventories are stated at the lower of first-in, first-out cost or market:
<TABLE>
<CAPTION>

                                                      As of                          As of
                                                 August 31, 2001                 May 31, 2001
                                              ----------------------         ----------------------
<S>                                                     <C>                            <C>
Raw materials and supplies                              $ 5,386,170                    $ 5,524,301
Work in process                                           1,980,989                      2,095,363
Finished goods                                            8,323,496                      8,048,973
                                              ----------------------         ----------------------
                                                        $15,690,655                    $15,668,637
                                              ======================         ======================
</TABLE>


3.  EARNINGS (LOSS) PER SHARE

The following table sets forth the computation of basic and diluted earnings per
share in accordance  with Statement of Financial  Accounting  Standards No. 128,
Earnings per Share.
<TABLE>
<CAPTION>

                                                         Three Months Ended
                                                     August 31,       August 31,
                                                        2001             2000
                                                   ---------------- ---------------
Numerator for basic and diluted
earnings(loss) per share:

<S>                                                     <C>             <C>
Income (loss) available to common shareholders          $1,252,676      $(215,431)
                                                   ================ ===============
Denominator:
  For basic earnings (loss) per share - weighted
      average basis                                      7,277,617       7,311,801
  Effect of dilutive stock options and warrants             18,615               -
                                                   ---------------- ---------------
  Denominator for diluted earnings (loss) per
     share-adjusted weighted-average shares              7,296,232       7,311,801
                                                   ================ ===============

Basic earnings (loss)  per share                             $0.17         $(0.03)
                                                   ================ ===============

Diluted earnings (loss) per share                            $0.17         $(0.03)
                                                   ================ ===============
</TABLE>



<PAGE>



4.  DOMESTIC AND FOREIGN OPERATIONS

Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):
<TABLE>
<CAPTION>

                               ---------------------------------------------------------------------------------------------------
                                                               Three Months Ended August 31, 2001
                               ---------------------------------------------------------------------------------------------------
                                 U.S.         Germany       Italy         Canada        Other       Eliminations     Consolidated
Net sales:
<S>                             <C>            <C>           <C>           <C>           <C>          <C>               <C>
   Unaffiliated customers       $12,468        $2,210        $1,424        $1,297        $1,241       $     -           $18,640
   Affiliates                     1,859           355             -            32           104        (2,350)                -
                               ----------    ----------    ---------     ----------    ---------    -------------    -------------
      Total                      14,327         2,565         1,424         1,329         1,345        (2,350)           18,640

Income from operations            1,134           202           121           346           175           (23)            1,955


                               ---------------------------------------------------------------------------------------------------
                                                               Three Months Ended August 31, 2000
                               ---------------------------------------------------------------------------------------------------
                                 U.S.         Germany       Italy         Canada        Other       Eliminations     Consolidated
Net sales:
   Unaffiliated customers       $10,660        $2,031        $1,415        $1,241        $1,734       $     -           $17,081
   Affiliates                     1,609            71             -            19            36        (1,735)                -
                               ----------    ----------    ---------     ----------    ---------    -------------    -------------
      Total                      12,269         2,102         1,415         1,260         1,770        (1,735)           17,081

(Loss) income from operations      (368)          366           177           313            89             -               577
</TABLE>



The Company's U.S. operation made net export sales to unaffiliated  customers of
approximately  $1,306,000  and  $1,666,000 for the three months ended August 31,
2001 and August 31, 2000, respectively.  The Company's German operation made net
export sales to unaffiliated  customers of  approximately  $897,000 and $217,000
for the three months  ended  August 31, 2001 and August 31, 2000,  respectively.
The Company's Canadian operation made net export sales to unaffiliated customers
of approximately  $570,000 and $545,000 for the three months August 31, 2001 and
August 31, 2000, respectively.  Product sales to affiliates are valued at market
prices.


5. COMPREHENSIVE INCOME (LOSS)

The components of comprehensive  income (loss) for the three-month  period ended
August 31, 2001 and August 31, 2000 are as follows:
<TABLE>
<CAPTION>

                                              Three Months Ended
                                       August 31,           August 31,
                                          2001                 2000
                                     ----------------     ----------------

<S>                                   <C>                  <C>
Net income (loss)                     $  1,252,676         $    (215,431)

Net foreign currency translation           951,502              (755,042)

Cumulative effect of the adoption
  of FAS 133 on June 1, 2001, net
  of taxes                                (102,721)                    -
                                     ----------------     ----------------
Comprehensive income (loss)           $  2,101,457          $   (970,473)
                                     ================     ================
</TABLE>

Accumulated  comprehensive  loss as of  August  31,  2001  and May 31,  2001 was
($5,737,031) and ($6,585,812),  respectively. The balance consists of net losses
on  foreign  currency  translation  adjustments  and has been  disclosed  in the
shareholders' equity section of the consolidated balance sheets.



<PAGE>


6.  LOANS TO OFFICERS AND DIRECTORS

     On June 6, 2000  Edward  L.  Gallup,  President  and CEO of  Immucor,  Inc.
entered into a loan  agreement  with  Immucor,  Inc. to borrow up to $400,000 in
order to meet margin  calls  related to loans made by brokerage  companies.  The
Company made the loan because it believed that certain  benefits would accrue to
the Company and its  shareholders  if such margin  calls were  satisfied by some
means other than having those shares sold by the broker.  The loan is payable on
demand by the Company and bears interest at the rate charged paid by the Company
under the Company's loan agreement with its principal lender (which presently is
the Prime Rate plus 0.5%).  The amount of principal  outstanding from Mr. Gallup
on October 11, 2001 is $358,000, and is secured by 105,000 Immucor shares.


7.  IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS

Effective January 1, 2001, the Company adopted Statement of Financial Accounting
Standards  No.  133,   "Accounting   for  Derivative   Instruments  and  Hedging
Activities"  ("Statement  No.  133").  Statement No. 133 requires the Company to
recognize all  derivatives on the balance sheet at fair value.  For  derivatives
designated as hedges, the change in the fair value of the derivative will either
be offset  against the change in the fair value of the hedged asset,  liability,
or firm commitment through earnings or recognized in other comprehensive  income
until the hedged item is recognized in earnings.  The  ineffective  portion of a
derivative's change in fair value will be immediately recognized in earnings. As
of August 31, 2001,  the Company had two interest rate swap  agreements to hedge
against exposure to interest rate risk. The cumulative effect of the adoption of
FAS  133 on June 1,  2001  resulted  in a  comprehensive  loss of  approximately
$103,000, relating to the interest rate swap agreements.

In June 2001,  the  Financial  Accounting  Standards  Board issued  Statement of
Financial  Accounting  Standards No. 141,  Business  Combinations,  and No. 142,
Goodwill  and Other  Intangible  Assets,  collectively,  the  Statements.  These
Statements drastically change the accounting for business combinations, goodwill
and intangible assets. Statement 141 eliminates the pooling-of-interests  method
of  accounting  for  business   combinations   except  for  qualifying  business
combinations  that were  initiated  prior to July 1,  2001.  Statement  141 also
changes the criteria to recognize  intangible assets apart from goodwill.  Under
Statement 142,  goodwill and indefinite  lived  intangible  assets are no longer
amortized  but are  reviewed  annually for  impairment,  or more  frequently  if
impairment indicators arise.  Separable intangible assets that have finite lives
will  continue  to be  amortized  over  their  useful  lives.  The  amortization
provisions of Statement  142 apply to goodwill and  intangible  assets  acquired
after June 30, 2001.  With respect to goodwill and  intangible  assets  acquired
prior  to July  1,  2001,  the  amortization  provisions  of  Statement  142 are
effective upon adoption of Statement 142.  Pre-existing goodwill and intangibles
will be amortized  during the transition  period until  adoption.  Companies are
required to adopt  Statement 142 in their fiscal year  beginning  after December
15, 2001.  Early adoption is permitted for companies with fiscal years beginning
after March 15, 2001. The Company plans to adopt Statement 142 effective June 1,
2002.



<PAGE>



8. INCOME TAX EXPENSE

Income tax expense as shown in the statements of consolidated  operations differ
from the  amount  that  would be  computed  if income  before  income  taxes was
multiplied  by the  United  States  federal  income  tax rate  (statutory  rate)
applicable in each period. The reasons for this difference are as follows:
<TABLE>
<CAPTION>

                                                      Three Months Ended
                                                 August 31,        August 31,
                                                    2001              2000
                                                    ----              ----

<S>                                            <C>             <C>
Expense at statutory rate                      $    502,052    $     (67,806)
Increase (decrease) resulting from:
   Amortization                                     138,656          164,591
   Dividend from subsidiary                         (42,028)        (179,390)
   Foreign operations                               148,400           57,427
   Domestic operating loss carryforward            (468,604)               -
   Other                                            (54,528)          41,180
                                           ------------------------------------
Tax provision per statement of operations    $      223,948      $    16,002
                                           ====================================
</TABLE>




ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results
            of Operations.

     Any statements  contained herein that are not statements of historical fact
are forward-looking statements as that term is defined in the Private Securities
Reform Act of 1995,  including,  without limitation,  statements  concerning the
Company's expectations,  beliefs, intentions or strategies regarding the future.
All  forward-looking  statements  included  in  this  discussion  are  based  on
information available to the Company on the date hereof, and the Company assumes
no obligation to update any such forward-looking  statements.  It is not certain
that the  Company  will  achieve  expected  sales and  earnings,  which could be
adversely  affected  by  a  variety  of  factors,  including  significant  price
decreases by our competitors,  the  strengthening of the dollar versus the euro,
and the  inability  of the  Company to  maintain  an  adequate  level of working
capital. In addition,  continued weakness in the economy and other factors could
cause  customers  to  defer  capital  spending,  which  would  adversely  impact
instrument sales.


Financial Condition and Liquidity:

As of August 31, 2001, the Company's cash position totaled $4.1 million.  During
the quarter the Company  improved net income by $1.5 million over the prior year
and received  $1.2  million  from the  settlement  with  Becton,  Dickinson  and
Company.  Debt  payments of $1.8  million and capital  additions of $0.6 million
were made during the quarter. The implementation of the cost savings plan in the
fourth  quarter of fiscal 2001 has had a positive  effect on the Company's  cash
position.  The  net  result  of  the  quarter's  cashflow  was  a  $1.3  million
improvement in cash position compared to the prior year.

On September 11, 2001 the Company successfully  completed  negotiations with its
primary  lender to issue a waiver  of  covenant  defaults  and to reset the loan
covenants for the next four quarters in the Loan  Agreement  dated  February 23,
2001.  A waiver fee of $750,000  will be paid in twelve equal  monthly  payments
beginning September 30, 2001. Any remaining balance will be paid upon receipt of
junior capital. The interest rate on the revolving lines of credit and Term Loan
A will be prime  plus 0.50% and the  interest  rate on Term Loan B will be prime
plus 2.00%.  The Company is required to meet  quarterly  and  cumulative  EBITDA
covenants  in  addition to  quarterly  funded  debt to EBITDA  ratios.  Once the
Company's trailing  twelve-month funded debt to EBITDA reaches 2.50 to 1 or less
the  Company  will  revert  back to the  pricing  matrix  as  stated in the Loan
Agreement.


<PAGE>



An additional  requirement of the waiver is that the Company successfully obtain
a minimum of $5.0 million in junior capital by December 31, 2001. If the Company
is not successful, the lender will earn an additional fee of $450,000 payable in
twelve equal monthly  installments  beginning  January 31, 2002. The lender will
also fully earn  warrants to purchase  750,000  shares of  Immucor,  Inc.  stock
issued at the then current  market price of the stock.  If the Company meets all
of its  quarterly  EBITDA  covenants  and no other  events of  default  are then
occurring, the lender will return a portion of the warrants to the Company based
on when  the  Company  raises  the  junior  capital  after  December  31,  2001.
Specifically,  562,500  warrants would be returned if the $5.0 million of junior
capital is raised by January 31, 2002, 375,000 warrants would be returned if the
$5.0  million of junior  capital is raised by  February  28,  2002,  and 187,500
warrants  would be returned if the $5.0  million of junior  capital is raised by
March 31, 2002. If the junior capital is not received by December 31, 2001, then
the  revolving  lines of credit and Term Note A would be re-priced at prime plus
2.0% and Term Note B would be  re-priced  at prime  plus 4.0%  until the  junior
capital is  received.  If the junior  capital is not received by April 30, 2002,
all existing credit facilities will be reset to mature on February 28, 2003.

The FDA agreed to lift the ABS2000 safety  notification  for antibody  screening
and crossmatch  assay in December  2000. The Company's  corrective  action plan,
for blood  grouping,  was  accepted by the FDA. In  connection  with the plan, a
special  510(k) was  submitted to the FDA.  The plan called for Company  service
engineers to complete field  corrective  action on the ABS2000 and to accumulate
clinical  data for group and type  assays for  selected  customers.  The Company
completed  these  tasks  and  submitted  data to the FDA for  expedited  review.
Instrument  sales for the first  quarter  of fiscal  2002 were  depressed,  as a
result.  On September 26, 2001, the Company received written  notification  from
the U.S. Food and Drug Administration (FDA) clearing the Company's  modification
to ABS2000 Version 1 software. This clearance effectively lifts the safety alert
for the instrument.  On October 1, 2001 the Company  announced that it began the
commercial launch of ABS2000 Version 2 software.  This simple  enhancement  will
be installed at no charge to the customer.  Immucor received Version 2 clearance
from the U.S. Food and Drug  Administration  on July 3, 2001 but could not begin
the  commercialization  process until the ABS2000  safety alert had been lifted.
The  expected  increase in  instrument  sales going  forward is expected to also
improve revenues.

Management  expects that the projected  savings from the cost savings plan, cash
and cash  equivalents  and  internally  generated  funds will be  sufficient  to
support  operations and planned capital  expenditures for the next 12 months. In
addition, Management believes that most capital expenditure planned for the next
12 months can be delayed in the event capital resources become inadequate.


Results of Operations:

Net sales

Revenues  for the quarter  ended  August 31, 2001 rose by $1.6  million over the
same quarter last fiscal year. The aggressive  price increase begun in the third
quarter of fiscal year 2001 had a positive  effect of $0.8  million on revenues.
The Company  expects to improve sales by $8.0 million for the fiscal year ending
May  31,  2002  as a  result  of the  price  increases.  Revenues  were  further
strengthened by the addition of revenues from a new purchasing  group added near
the end of the fiscal  year 2001.  This group  contract  is expected to increase
revenues by $2.5 million for the fiscal year.  Instrument  sales for the quarter
ended August 31, 2001 were up slightly to $0.8  million  from $0.75  million for
the same  quarter in the prior  year.  With the  lifting of the  ABS2000  safety
alert, instrument sales are expected to return to previous levels.

Gross profit

Gross profit increased $0.75 million as compared to the prior year's quarter due
to the aggressive price increases  mentioned above. In addition,  costs incurred
to resolve the ABS2000  issue and reagents  provided free of charge to customers
performing backup testing were substantially reduced by the beginning of the new
fiscal year.


<PAGE>



Operating expenses

When  compared  to the prior  year,  research  and  development  costs  remained
relatively constant, primarily related to instrument development initiatives for
the Galileo for the European  market.  The project is  continuing on track for a
launch in late calendar  year 2001.  The Galileo is designed to fulfill the need
in Europe for a high-throughput blood  serology-testing  device with a test menu
that includes antibody screening.

Selling and marketing  expenses  decreased  $0.7 million as compared to the same
period last year.  Until the fourth quarter of fiscal 2001, the Company had been
developing an  infrastructure to support an increased level of instrument sales.
But in light of the issues with the ABS2000, at the time, and continued customer
migration to purchasing groups,  the Company  reevaluated the focus of the sales
and  marketing   efforts.   The  domestic  and   Netherlands   sales  staff  was
significantly reduced and had a positive effect on the first quarter net income.
In  addition,  in the prior  year  quarter, the  Company  recorded  $160,000  in
additional expense  related to the ABS2000 problems.

Distribution  expenses for the first quarter of fiscal 2002 remained  relatively
constant  as  compared to the prior year,  but as a  percentage  of sales,  have
decreased from 8.4% to 7.7%.  Additional  shipping  expenses  related to the new
purchasing group were offset by volume discounts offered by carriers.

General and administrative expenses and amortization expense remained relatively
constant with the prior period.

Interest expense

When compared to the prior year three-month  period,  interest expense increased
$287,000.  This is the result of  increased  borrowings  on  long-term  debt and
capitalized leases in fiscal 2001.

Other income

Other income for the first quarter of fiscal 2002 was favorably  affected by the
settlement  of the  Becton,  Dickinson  arbitration.  On  December  28, 2000 the
Company  initiated  arbitration  against Becton,  Dickinson and Company with the
American   Arbitration   Association  to  take  place  in  Santa  Clara  County,
California.  The Company's claims against Becton,  Dickinson and Company related
to a Distributor Agreement between the Company and Biometric Imaging,  Inc., and
Becton,  Dickinson  and  Company  became a party  to this  agreement  when  they
acquired  Biometric  Imaging,  Inc.  in 1999.  On June  12,  2001,  the  Company
announced that it had reached a settlement  with Becton,  Dickinson and Company.
The settlement  called for Becton to pay Immucor,  Inc. a total of $1.8 million,
payable in two installments.  The first payment of $1.2 million was made on June
11, 2001,  with the second  installment  of $0.6 million  payable not later than
April 1, 2002. This settlement  represents a reimbursement  for asset impairment
and lost  profits.  In  return,  Immucor,  Inc.  agreed  to give up its right to
distribute the IMAGN  instrument  and associated  reagents in Italy and Portugal
and to cooperate  with Becton,  Dickinson  and Company in the  transition of the
Italian and Portuguese  IMAGN customers.  Assets of  approximately  $1.0 million
related to IMAGN were written off with the transaction.

Income taxes

Income tax expense  increased  during the  three-month  period  ended August 31,
2001, as compared to the prior period,  due mainly to income from  operations at
the foreign subsidiaries.  During the fourth quarter of fiscal 2001, the Company
elected to record a valuation  allowance  in an amount equal to the net deferred
tax assets of the Company, amounting to $1.2 million. Effectively, this non-cash
allowance  reflected the  elimination  of domestic  deferred  taxes as a balance
sheet asset and will be used to reduce  domestic  taxes in the current  year now
that the Company has returned to profitability.


<PAGE>



ITEM 3.  Quantitative and Qualitative Disclosures On Market Risk

There have been no material changes regarding the Company's market risk position
from the  information  provided in its Annual Report on Form 10-K for the fiscal
year ended May 31, 2001. The  quantitative  and  qualitative  disclosures  about
market risk are discussed in Item  7A-Quantitative  and Qualitative  Disclosures
About Market Risk, contained in the Company's Form 10-K.



                                     PART II

                                OTHER INFORMATION
Item 6.  Exhibits and Reports on Form 8-K.

         (a) The Company has filed the following exhibits with this report:

          3.1  Amended and Restated  Articles of Incorporation  (incorporated by
               reference to Exhibit 3.1 to Immucor,  Inc.'s  quarterly report on
               Form 10-Q filed on January 16, 2001).

          3.2  Amended and Restated  Bylaws (amended and restated as of November
               29, 2000)  (incorporated  by reference to Exhibit 3.2 to Immucor,
               Inc.'s quarterly report on Form 10-Q filed on January 16, 2001).

          4.1  Immucor,  Inc.  Shareholder  Rights Plan,  adopted April 16, 1999
               (incorporated  by  reference  to  Exhibit  1 to  Immucor,  Inc.'s
               Current Report on Form 8-K dated April 16, 1999).

          4.2  Amendment  No. 1 dated as of  November  29,  2000 to  Shareholder
               Rights  Agreement  between  Immucor,  Inc.  and  EQUISERVE  Trust
               Company,  N.A.  (incorporated  by  reference  to  Exhibit  4.2 to
               Immucor Inc.'s quarterly report on Form 10-Q filed on January 16,
               2001.

          (b)  The Company did not file any reports on Form 8-K during the three
               months ended August 31, 2001.



<PAGE>


                                   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                  IMMUCOR, INC.
                                  (Registrant)



Date: October 15, 2001








_/s/ Edward L. Gallup______    Edward L. Gallup, President
                               (Principal Executive Officer)






_/s/ Steven C. Ramsey_____     Steven C. Ramsey, Senior Vice President - Finance
                               (Principal Accounting Officer)



<PAGE>





EXHIBIT INDEX


Number                                      Description

3.1       Amended  and  Restated  Articles  of  Incorporation  (incorporated  by
          reference to Exhibit 3.1 to Immucor,  Inc.'s  Quarterly Report on Form
          10-Q for the fiscal quarter filed on January 16, 2001).

3.2       Amended and Restated  Bylaws  (amended and restated as of November 29,
          2000)  (incorporated  by reference  to Exhibit 3.2 to Immucor,  Inc.'s
          Quarterly Report on Form 10-Q filed on January 16, 2001).

4.1       Immucor,   Inc.  Shareholder  Rights  Plan,  adopted  April  16,  1999
          (incorporated  by  reference to Exhibit 1 to Immucor,  Inc.'s  Current
          Report on Form 8-K dated April 16, 1999).

4.2       Amendment  No. 1 dated as of November 29, 2000 to  Shareholder  Rights
          Agreememt  between  Immucor,  Inc. and EQUISERVE  Trust Company,  N.A.
          (incorporated  by reference to Exhibit 4.2 to Immucor Inc.'s quarterly
          report on Form 10-Q filed on January 16, 2001.